07:00 , Jul 14, 2014 |  BC Week In Review  |  Company News

Santaris, Servier, miRagen deal

The partners extended by two years to October 2016 a 2011 deal to develop and commercialize microRNA-targeting products for cardiovascular disease. The deal includes miRagen’s preclinical programs targeting microRNA-208 ( miR-208 ) and miR-15/195 ,...
07:00 , Jun 3, 2013 |  BC Week In Review  |  Company News

miRagen, Santaris, Servier deal

Servier exercised its right to add a third target to a 2011 deal with miRagen to develop and commercialize microRNA-targeting products for cardiovascular disease. Servier's target selection triggered the first undisclosed milestone payment to miRagen....
08:00 , Nov 7, 2011 |  BioCentury  |  Strategy

Servicing CV

While some pharmas have concluded cardiovascular disease is well served by generics and are exiting the space, Servier believes it can grow its CV business by in-licensing novel, first-in-class programs. Last month, Servier agreed to...
07:00 , Oct 24, 2011 |  BC Week In Review  |  Company News

miRagen, Santaris, Servier deal

Servier partnered with miRagen to develop and commercialize microRNA-targeting products for cardiovascular disease. The deal includes miRagen's preclinical programs targeting microRNA-208 ( miR-208 ) and miR-15/195, as well as a cardiovascular microRNA modulator yet to...
00:34 , Oct 19, 2011 |  BC Extra  |  Top Story

Servier, miRagen in cardiovascular deal

Servier (Neuilly-sur-Seine, France) partnered with miRagen Therapeutics Inc. (Boulder, Colo.) to develop and commercialize microRNA-targeting products for cardiovascular disease. The deal includes miRagen's preclinical programs targeting microRNA-208 (miR-208) and miR-15/195, as well as a cardiovascular...